Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.
A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.